IRWD
Ironwood Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
4.54 / 10
Netural
Analyst sentiment is split between Buy (50%) and Neutral (50%) with only two active analysts, resulting in a low-confidence historical weighted rating of 1.39. Money flow is robust at 7.68/10, with positive Small and Medium inflows but negative overall and Extra-large trends, indicating that while retail and mid-sized investors are accumulating, larger institutions are exiting. This divergence underscores a cautious outlook, as sustained institutional support is lacking to propel the stock higher.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-05
InstitutionCitizens
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for IRWD?
- IRWD holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.54/10 (Netural).
